Skip to main content
Top
Published in: Clinical & Experimental Metastasis 6-7/2017

01-10-2017 | Research Paper

Metabolic advantages and vulnerabilities in brain metastases

Authors: Alexandra K. Ciminera, Rahul Jandial, John Termini

Published in: Clinical & Experimental Metastasis | Issue 6-7/2017

Login to get access

Abstract

Metabolic adaptations permit tumor cells to metastasize to and thrive in the brain. Brain metastases continue to present clinical challenges due to rising incidence and resistance to current treatments. Therefore, elucidating altered metabolic pathways in brain metastases may provide new therapeutic targets for the treatment of aggressive disease. Due to the high demand for glucose in the brain, increased glycolytic activity is favored for energy production. Primary tumors that undergo Warburg-like metabolic reprogramming become suited to growth in the brain microenvironment. Indeed, elevated metabolism is a predictor of metastasis in many cancer subtypes. Specifically, metabolic alterations are seen in primary tumors that are associated with the formation of brain metastases, namely breast cancer, lung cancer, and melanoma. Because of this selective pressure, inhibitors of key metabolic factors may reduce tumor cell viability, thus exploiting metabolic pathways for cancer therapeutics. This review summarizes the metabolic advantages and vulnerabilities of brain metastases.
Literature
1.
2.
3.
go back to reference Markesbery WR, Brooks WH, Gupta GD, Young AB (1978) Treatment for patients with cerebral metastases. Arch Neurol 35:754–756CrossRefPubMed Markesbery WR, Brooks WH, Gupta GD, Young AB (1978) Treatment for patients with cerebral metastases. Arch Neurol 35:754–756CrossRefPubMed
4.
go back to reference Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425CrossRefPubMed Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30:419–425CrossRefPubMed
5.
go back to reference Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36:587–597CrossRefPubMedPubMedCentral Mergenthaler P, Lindauer U, Dienel GA, Meisel A (2013) Sugar for the brain: the role of glucose in physiological and pathological brain function. Trends Neurosci 36:587–597CrossRefPubMedPubMedCentral
7.
go back to reference Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRefPubMedPubMedCentral Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029–1033CrossRefPubMedPubMedCentral
8.
go back to reference Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107–120CrossRefPubMed Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126:107–120CrossRefPubMed
9.
go back to reference Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–93CrossRefPubMed Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683–93CrossRefPubMed
10.
go back to reference Larkin JR, Dickens AM, Claridge TD, Bristow C, Andreou K, Anthony DC, Sibson NR (2016) Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics 6:2161–2169CrossRefPubMedPubMedCentral Larkin JR, Dickens AM, Claridge TD, Bristow C, Andreou K, Anthony DC, Sibson NR (2016) Early diagnosis of brain metastases using a biofluids-metabolomics approach in mice. Theranostics 6:2161–2169CrossRefPubMedPubMedCentral
12.
go back to reference Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Mates JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ, Bachoo RM (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15:827–837CrossRefPubMedPubMedCentral Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, Rajagopalan KN, Maddie M, Vemireddy V, Zhao Z, Cai L, Good L, Tu BP, Hatanpaa KJ, Mickey BE, Mates JM, Pascual JM, Maher EA, Malloy CR, Deberardinis RJ, Bachoo RM (2012) Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab 15:827–837CrossRefPubMedPubMedCentral
13.
go back to reference Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8CrossRefPubMedPubMedCentral Witzel I, Oliveira-Ferrer L, Pantel K, Muller V, Wikman H (2016) Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res 18:8CrossRefPubMedPubMedCentral
14.
go back to reference Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ, Lee MS, Kim H, Joo KM, Lee DS, Price JE, Bang SI, Park WY (2008) Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 14:4059–4066CrossRefPubMed Nam DH, Jeon HM, Kim S, Kim MH, Lee YJ, Lee MS, Kim H, Joo KM, Lee DS, Price JE, Bang SI, Park WY (2008) Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 14:4059–4066CrossRefPubMed
16.
go back to reference Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Wilber A, Mo YY, Moore BE, Liu W, Fukuda K, Iiizumi M, Sharma S, Liu Y, Wu K, Peralta E, Watabe K (2013) Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol Med 5:384–396CrossRefPubMedPubMedCentral Xing F, Kobayashi A, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Wilber A, Mo YY, Moore BE, Liu W, Fukuda K, Iiizumi M, Sharma S, Liu Y, Wu K, Peralta E, Watabe K (2013) Reactive astrocytes promote the metastatic growth of breast cancer stem-like cells by activating Notch signalling in brain. EMBO Mol Med 5:384–396CrossRefPubMedPubMedCentral
17.
go back to reference McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, Chambers AF (2011) Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9:834–844CrossRefPubMedPubMedCentral McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, Chambers AF (2011) Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9:834–844CrossRefPubMedPubMedCentral
19.
go back to reference Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114CrossRefPubMed Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, Foekens JA, Martens JW (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114CrossRefPubMed
20.
go back to reference Liu Z, Sneve M, Haroldson TA, Smith JP, Drewes LR (2016) Regulation of monocarboxylic acid transporter 1 trafficking by the canonical Wnt/beta-catenin pathway in rat brain endothelial cells requires cross-talk with notch signaling. J Biol Chem 291:8059–8069CrossRefPubMedPubMedCentral Liu Z, Sneve M, Haroldson TA, Smith JP, Drewes LR (2016) Regulation of monocarboxylic acid transporter 1 trafficking by the canonical Wnt/beta-catenin pathway in rat brain endothelial cells requires cross-talk with notch signaling. J Biol Chem 291:8059–8069CrossRefPubMedPubMedCentral
21.
go back to reference Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PA, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR (2016) MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep 14:1590–1601CrossRefPubMedPubMedCentral Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PA, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR (2016) MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4. Cell Rep 14:1590–1601CrossRefPubMedPubMedCentral
22.
go back to reference Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Yu D, Da Silva L, Simpson PT, Khanna KK, Chenevix-Trench G, Lakhani SR (2015) Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget 6:3932–3946CrossRefPubMedPubMedCentral Momeny M, Saunus JM, Marturana F, McCart Reed AE, Black D, Sala G, Iacobelli S, Holland JD, Yu D, Da Silva L, Simpson PT, Khanna KK, Chenevix-Trench G, Lakhani SR (2015) Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines. Oncotarget 6:3932–3946CrossRefPubMedPubMedCentral
23.
go back to reference Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Muller V, Pantel K, Wikman H (2013) Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am J Pathol 183:83–95CrossRefPubMed Hohensee I, Lamszus K, Riethdorf S, Meyer-Staeckling S, Glatzel M, Matschke J, Witzel I, Westphal M, Brandt B, Muller V, Pantel K, Wikman H (2013) Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. Am J Pathol 183:83–95CrossRefPubMed
24.
go back to reference Yatabe Y, Takahashi T, Mitsudomi T (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106–2111CrossRefPubMed Yatabe Y, Takahashi T, Mitsudomi T (2008) Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68:2106–2111CrossRefPubMed
25.
go back to reference Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Muller V, Westphal M, Pantel K (2012) Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 14:R49CrossRefPubMedPubMedCentral Wikman H, Lamszus K, Detels N, Uslar L, Wrage M, Benner C, Hohensee I, Ylstra B, Eylmann K, Zapatka M, Sauter G, Kemming D, Glatzel M, Muller V, Westphal M, Pantel K (2012) Relevance of PTEN loss in brain metastasis formation in breast cancer patients. Breast Cancer Res 14:R49CrossRefPubMedPubMedCentral
27.
go back to reference Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ (2010) Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12:748–754CrossRefPubMedPubMedCentral Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, Aldape KD, Fidler IJ (2010) Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12:748–754CrossRefPubMedPubMedCentral
28.
go back to reference Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC, Fidler IJ (2011) Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13:286–298CrossRefPubMedPubMedCentral Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC, Fidler IJ (2011) Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13:286–298CrossRefPubMedPubMedCentral
29.
go back to reference Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, Regen T, Van Rossum D, Klemm F, Schulz M, Siam L, Hoffmann A, Trumper L, Stadelmann C, Bechmann I, Hanisch UK, Binder C (2010) Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58:1477–1489PubMed Pukrop T, Dehghani F, Chuang HN, Lohaus R, Bayanga K, Heermann S, Regen T, Van Rossum D, Klemm F, Schulz M, Siam L, Hoffmann A, Trumper L, Stadelmann C, Bechmann I, Hanisch UK, Binder C (2010) Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58:1477–1489PubMed
30.
go back to reference Sierra A, Price JE, Garcia-Ramirez M, Mendez O, Lopez L, Fabra A (1997) Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77:357–368PubMed Sierra A, Price JE, Garcia-Ramirez M, Mendez O, Lopez L, Fabra A (1997) Astrocyte-derived cytokines contribute to the metastatic brain specificity of breast cancer cells. Lab Invest 77:357–368PubMed
32.
go back to reference Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527:100–104CrossRefPubMedPubMedCentral Zhang L, Zhang S, Yao J, Lowery FJ, Zhang Q, Huang WC, Li P, Li M, Wang X, Zhang C, Wang H, Ellis K, Cheerathodi M, McCarty JH, Palmieri D, Saunus J, Lakhani S, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D (2015) Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527:100–104CrossRefPubMedPubMedCentral
33.
go back to reference Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E, Jandial R (2014) Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA 111:984-989CrossRefPubMedCentral Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, Li H, Hambrecht AC, Roberts E, Jandial R (2014) Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci USA 111:984-989CrossRefPubMedCentral
34.
go back to reference Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159:1603–1614CrossRefPubMedPubMedCentral Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159:1603–1614CrossRefPubMedPubMedCentral
35.
go back to reference Mohamed A, Deng X, Khuri FR, Owonikoko TK (2014) Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer 15:7–15CrossRefPubMed Mohamed A, Deng X, Khuri FR, Owonikoko TK (2014) Altered glutamine metabolism and therapeutic opportunities for lung cancer. Clin Lung Cancer 15:7–15CrossRefPubMed
36.
go back to reference Filipp FV, Ratnikov B, De Ingeniis J, Smith JW, Osterman AL, Scott DA (2012) Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25:732–739CrossRefPubMedPubMedCentral Filipp FV, Ratnikov B, De Ingeniis J, Smith JW, Osterman AL, Scott DA (2012) Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25:732–739CrossRefPubMedPubMedCentral
38.
go back to reference Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, Luo K, Nomura DK (2013) Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci USA 110:14912-14917CrossRefPubMedCentral Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Mulvihill MM, Luo K, Nomura DK (2013) Ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids to fuel cancer pathogenicity. Proc Natl Acad Sci USA 110:14912-14917CrossRefPubMedCentral
39.
go back to reference Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL (2013) Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24:1526–1533CrossRefPubMedPubMedCentral Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL (2013) Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24:1526–1533CrossRefPubMedPubMedCentral
40.
go back to reference Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 13:R87CrossRefPubMedPubMedCentral Sihto H, Lundin J, Lundin M, Lehtimaki T, Ristimaki A, Holli K, Sailas L, Kataja V, Turpeenniemi-Hujanen T, Isola J, Heikkila P, Joensuu H (2011) Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res 13:R87CrossRefPubMedPubMedCentral
41.
go back to reference Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRefPubMed Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271–3277CrossRefPubMed
42.
go back to reference Choi J, Kim DH, Jung WH, Koo JS (2013) Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res 15:R78CrossRefPubMedPubMedCentral Choi J, Kim DH, Jung WH, Koo JS (2013) Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype. Breast Cancer Res 15:R78CrossRefPubMedPubMedCentral
43.
go back to reference Taylor S, Lam M, Pararasa C, Brown JE, Carmichael AR, Griffiths HR (2015) Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review. Cancer Cell Int 15:1CrossRefPubMedPubMedCentral Taylor S, Lam M, Pararasa C, Brown JE, Carmichael AR, Griffiths HR (2015) Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review. Cancer Cell Int 15:1CrossRefPubMedPubMedCentral
44.
go back to reference Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem Biol 23:567–578CrossRefPubMedPubMedCentral Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, Nomura DK (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. Cell Chem Biol 23:567–578CrossRefPubMedPubMedCentral
45.
go back to reference Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC (2016) EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape. Cancer Res 76:1284–1296CrossRefPubMedPubMedCentral Lim SO, Li CW, Xia W, Lee HH, Chang SS, Shen J, Hsu JL, Raftery D, Djukovic D, Gu H, Chang WC, Wang HL, Chen ML, Huo L, Chen CH, Wu Y, Sahin A, Hanash SM, Hortobagyi GN, Hung MC (2016) EGFR signaling enhances aerobic glycolysis in triple-negative breast cancer cells to promote tumor growth and immune escape. Cancer Res 76:1284–1296CrossRefPubMedPubMedCentral
46.
go back to reference Shen L, O’Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE (2015) Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA 112:5425-5430PubMedCentral Shen L, O’Shea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE (2015) Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci USA 112:5425-5430PubMedCentral
47.
go back to reference Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R, Yan GR (2015) MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget 6:32701–32712CrossRefPubMedPubMedCentral Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R, Yan GR (2015) MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget 6:32701–32712CrossRefPubMedPubMedCentral
48.
go back to reference Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P (2012) MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol 25:378–387CrossRefPubMed Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P (2012) MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Mod Pathol 25:378–387CrossRefPubMed
49.
go back to reference Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR (2015) Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Mol Cancer Ther 14:298–306CrossRefPubMed Fink LS, Beatty A, Devarajan K, Peri S, Peterson JR (2015) Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes. Mol Cancer Ther 14:298–306CrossRefPubMed
50.
go back to reference Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20:e300–306CrossRefPubMedPubMedCentral Ali A, Goffin JR, Arnold A, Ellis PM (2013) Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases. Curr Oncol 20:e300–306CrossRefPubMedPubMedCentral
51.
go back to reference Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon, MG, de Geus-Oei LF, van der Drift MA, van der Heijden EH, Oyen WJ, Visser EP, Span PN, Bussink J (2014) Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol 9:1485–1493CrossRefPubMed Schuurbiers OC, Meijer TW, Kaanders JH, Looijen-Salamon, MG, de Geus-Oei LF, van der Drift MA, van der Heijden EH, Oyen WJ, Visser EP, Span PN, Bussink J (2014) Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. J Thorac Oncol 9:1485–1493CrossRefPubMed
52.
go back to reference Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ (2013) LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23:143–158CrossRefPubMedPubMedCentral Shackelford DB, Abt E, Gerken L, Vasquez DS, Seki A, Leblanc M, Wei L, Fishbein MC, Czernin J, Mischel PS, Shaw RJ (2013) LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell 23:143–158CrossRefPubMedPubMedCentral
53.
go back to reference Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, Roberts P, Lee CB, Parsons AM, Thorne LB, Haithcock BE, Grilley-Olson JE, Stinchcombe TE, Funkhouser WK, Wong KK, Sharpless NE, Hayes DN (2014) Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 86:255–261CrossRefPubMedPubMedCentral Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, Roberts P, Lee CB, Parsons AM, Thorne LB, Haithcock BE, Grilley-Olson JE, Stinchcombe TE, Funkhouser WK, Wong KK, Sharpless NE, Hayes DN (2014) Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. Lung Cancer 86:255–261CrossRefPubMedPubMedCentral
54.
go back to reference Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer T (2012) Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 46:54–59CrossRefPubMedPubMedCentral Lekic M, Kovac V, Triller N, Knez L, Sadikov A, Cufer T (2012) Outcome of small cell lung cancer (SCLC) patients with brain metastases in a routine clinical setting. Radiol Oncol 46:54–59CrossRefPubMedPubMedCentral
55.
go back to reference Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, Moon JW, Park IK, Choi HJ, Kim JH (2009) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res15:2426–2432CrossRefPubMed Lee YJ, Cho A, Cho BC, Yun M, Kim SK, Chang J, Moon JW, Park IK, Choi HJ, Kim JH (2009) High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer. Clin Cancer Res15:2426–2432CrossRefPubMed
56.
go back to reference Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT (2014) Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:2PubMedPubMedCentral Park SB, Choi JY, Moon SH, Yoo J, Kim H, Ahn YC, Ahn MJ, Park K, Kim BT (2014) Prognostic value of volumetric metabolic parameters measured by [18F]fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer. Cancer Imaging 14:2PubMedPubMedCentral
57.
go back to reference Fischer B, Marinov M, Arcaro A (2007) Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33:391–406CrossRefPubMed Fischer B, Marinov M, Arcaro A (2007) Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 33:391–406CrossRefPubMed
58.
go back to reference Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901CrossRefPubMedPubMedCentral Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curtis CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901CrossRefPubMedPubMedCentral
59.
go back to reference Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 363:809–819CrossRefPubMedPubMedCentral Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O’Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 363:809–819CrossRefPubMedPubMedCentral
60.
go back to reference Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E (2014) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience 1:82–94CrossRefPubMedPubMedCentral Nygaard V, Prasmickaite L, Vasiliauskaite K, Clancy T, Hovig E (2014) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience 1:82–94CrossRefPubMedPubMedCentral
61.
go back to reference Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP (2015) The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer 136:1296–1307CrossRefPubMed Izraely S, Sagi-Assif O, Klein A, Meshel T, Ben-Menachem S, Zaritsky A, Ehrlich M, Prieto VG, Bar-Eli M, Pirker C, Berger W, Nahmias C, Couraud PO, Hoon DS, Witz IP (2015) The metastatic microenvironment: Claudin-1 suppresses the malignant phenotype of melanoma brain metastasis. Int J Cancer 136:1296–1307CrossRefPubMed
62.
go back to reference Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Oyjord T, Risa O, Nygaard V, Maelandsmo GM, Prasmickaite L (2015) Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Lett 366:71–83CrossRefPubMed Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Oyjord T, Risa O, Nygaard V, Maelandsmo GM, Prasmickaite L (2015) Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Lett 366:71–83CrossRefPubMed
63.
go back to reference Rodrigues MF, Obre E, de Melo FH, Santos GC Jr, Galina A, Jasiulionis MG, Rossignol R, Rumjanek FD, Amoedo ND (2016) Enhanced OXPHOS, glutaminolysis and beta-oxidation constitute the metastatic phenotype of melanoma cells. Biochem J 473:703–715CrossRefPubMed Rodrigues MF, Obre E, de Melo FH, Santos GC Jr, Galina A, Jasiulionis MG, Rossignol R, Rumjanek FD, Amoedo ND (2016) Enhanced OXPHOS, glutaminolysis and beta-oxidation constitute the metastatic phenotype of melanoma cells. Biochem J 473:703–715CrossRefPubMed
64.
go back to reference Le Rhun E, Dhermain F, Vogin G, Reyns N, Metellus P. (2016) Radionecrosis after stereotactic radiotherapy for brain metastases. Expert Rev Neurother Le Rhun E, Dhermain F, Vogin G, Reyns N, Metellus P. (2016) Radionecrosis after stereotactic radiotherapy for brain metastases. Expert Rev Neurother
65.
go back to reference Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26:113–119CrossRefPubMed Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, Miles D, Samant M, Welslau M, Dieras V (2015) Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol 26:113–119CrossRefPubMed
66.
go back to reference Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71CrossRefPubMed Bachelot T, Romieu G, Campone M, Dieras V, Cropet C, Dalenc F, Jimenez M, Le Rhun E, Pierga JY, Goncalves A, Leheurteur M, Domont J, Gutierrez M, Cure H, Ferrero JM, Labbe-Devilliers C (2013) Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol 14:64–71CrossRefPubMed
67.
go back to reference Zhao X, Zhu G, Chen H, Yang P, Li F, Du N (2014) Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. J Cancer Res Ther 10(7):155–159CrossRef Zhao X, Zhu G, Chen H, Yang P, Li F, Du N (2014) Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation. J Cancer Res Ther 10(7):155–159CrossRef
68.
69.
go back to reference Stricker T, Arteaga CL (2015) Drug-resistant brain metastases: a role for pharmacology, tumor evolution, and too-late therapy. Cancer Discov 5:1124–1126CrossRefPubMed Stricker T, Arteaga CL (2015) Drug-resistant brain metastases: a role for pharmacology, tumor evolution, and too-late therapy. Cancer Discov 5:1124–1126CrossRefPubMed
70.
go back to reference Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51CrossRefPubMed Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED (2007) A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51CrossRefPubMed
71.
go back to reference Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, Felitsyn NM, Gilmore RL, Greer M, Henderson GN, Hutson AD, Neiberger RE, O’Brien RG, Perkins LA, Quisling RG, Shroads AL, Shuster JJ, Silverstein JH, Theriaque DW, Valenstein E (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519–1531CrossRefPubMed Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, Felitsyn NM, Gilmore RL, Greer M, Henderson GN, Hutson AD, Neiberger RE, O’Brien RG, Perkins LA, Quisling RG, Shroads AL, Shuster JJ, Silverstein JH, Theriaque DW, Valenstein E (2006) Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519–1531CrossRefPubMed
72.
go back to reference Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD, Michelakis ED (2016) Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur Urol 69:734–744CrossRefPubMed Kinnaird A, Dromparis P, Saleme B, Gurtu V, Watson K, Paulin R, Zervopoulos S, Stenson T, Sutendra G, Pink DB, Carmine-Simmen K, Moore R, Lewis JD, Michelakis ED (2016) Metabolic modulation of clear-cell renal cell carcinoma with dichloroacetate, an inhibitor of pyruvate dehydrogenase kinase. Eur Urol 69:734–744CrossRefPubMed
73.
go back to reference Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharmaceut Biopharmaceut 71:409–419CrossRef Maeda H, Bharate GY, Daruwalla J (2009) Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharmaceut Biopharmaceut 71:409–419CrossRef
74.
go back to reference Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S. (2008) Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 87:287–294CrossRefPubMed Doi A, Kawabata S, Iida K, Yokoyama K, Kajimoto Y, Kuroiwa T, Shirakawa T, Kirihata M, Kasaoka S, Maruyama K, Kumada H, Sakurai Y, Masunaga S, Ono K, Miyatake S. (2008) Tumor-specific targeting of sodium borocaptate (BSH) to malignant glioma by transferrin-PEG liposomes: a modality for boron neutron capture therapy. J Neurooncol 87:287–294CrossRefPubMed
75.
go back to reference Chen Y, Liu L. (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64:640–665CrossRefPubMed Chen Y, Liu L. (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64:640–665CrossRefPubMed
76.
go back to reference Soni V, Kohli DV, Jain SK. (2008) Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 16:73–78CrossRefPubMed Soni V, Kohli DV, Jain SK. (2008) Transferrin-conjugated liposomal system for improved delivery of 5-fluorouracil to brain. J Drug Target 16:73–78CrossRefPubMed
77.
go back to reference Gan HK, Kaye AH, Luwor RB. (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748–754CrossRefPubMed Gan HK, Kaye AH, Luwor RB. (2009) The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 16:748–754CrossRefPubMed
78.
go back to reference Ge H, Gong X, Tang CK. (2002) Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98:357–361CrossRefPubMed Ge H, Gong X, Tang CK. (2002) Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98:357–361CrossRefPubMed
Metadata
Title
Metabolic advantages and vulnerabilities in brain metastases
Authors
Alexandra K. Ciminera
Rahul Jandial
John Termini
Publication date
01-10-2017
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 6-7/2017
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-017-9864-8

Other articles of this Issue 6-7/2017

Clinical & Experimental Metastasis 6-7/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine